drugset / Trial / NCT00992407
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of long acting injectable (LAI) risperidone and oral risperidone treatment on participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) or schizoaffective disorder (a mixed psychiatric disorder relating to a complex psychotic state that has features of both schizophrenia and a mood disorder such as bipolar disorder).
Timeline
- Start
- 2007-12
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 0.5 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 10 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 25 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 37.5 mg | Intramuscular |
| Subject | Risperidone | Other / unclassified | 50 mg | Intramuscular |